HC Wainwright Predicts Annexon’s Q2 Earnings (NASDAQ:ANNX)

Annexon, Inc. (NASDAQ:ANNX) – Stock analysts at HC Wainwright raised their Q2 2026 EPS estimates for shares of Annexon in a report released on Friday, May 8th. HC Wainwright analyst A. Ghosh now anticipates that the company will earn ($0.23) per share for the quarter, up from their prior forecast of ($0.31). The consensus estimate for Annexon’s current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Annexon’s Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.29) EPS and FY2029 earnings at $0.13 EPS.

A number of other analysts have also recently weighed in on ANNX. Wall Street Zen upgraded shares of Annexon from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research note on Monday, April 20th. The Goldman Sachs Group started coverage on shares of Annexon in a research note on Tuesday. They set a “neutral” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Wednesday, January 14th. Finally, Chardan Capital reiterated a “buy” rating and set a $16.00 price target on shares of Annexon in a research note on Friday, March 20th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Annexon has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Annexon Price Performance

Shares of NASDAQ:ANNX opened at $5.68 on Tuesday. The stock has a market cap of $930.61 million, a P/E ratio of -4.66 and a beta of 1.22. The firm has a fifty day moving average price of $5.71 and a 200 day moving average price of $5.12. Annexon has a 1-year low of $1.67 and a 1-year high of $7.18.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07.

Insider Buying and Selling

In other news, EVP Dean Richard Artis sold 5,290 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total value of $26,979.00. Following the completion of the sale, the executive vice president owned 123,487 shares in the company, valued at approximately $629,783.70. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jennifer Lew sold 7,851 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.11, for a total transaction of $40,118.61. Following the completion of the sale, the chief financial officer owned 113,765 shares of the company’s stock, valued at $581,339.15. This trade represents a 6.46% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 32,513 shares of company stock worth $165,973. 12.67% of the stock is currently owned by insiders.

Institutional Trading of Annexon

Several hedge funds have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Annexon by 13.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 19,553 shares of the company’s stock worth $100,000 after acquiring an additional 2,348 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after acquiring an additional 2,785 shares during the period. Susquehanna Portfolio Strategies LLC lifted its stake in shares of Annexon by 0.8% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 356,619 shares of the company’s stock worth $1,790,000 after acquiring an additional 2,875 shares during the period. ProShare Advisors LLC lifted its stake in shares of Annexon by 21.7% in the 4th quarter. ProShare Advisors LLC now owns 24,698 shares of the company’s stock worth $124,000 after acquiring an additional 4,410 shares during the period. Finally, Citizens Financial Group Inc. RI lifted its stake in shares of Annexon by 14.3% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock worth $122,000 after acquiring an additional 5,000 shares during the period.

Key Headlines Impacting Annexon

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright raised its earnings outlook for Annexon (ANNX) across multiple periods, including FY2026, FY2027, FY2028, FY2029, and quarterly estimates for Q2-Q4 2026. The firm now expects smaller losses in the near term and a shift to profitability by FY2029, which can support sentiment toward the stock. Article source
• Neutral Sentiment: The latest earnings update from HC Wainwright follows Annexon’s recent quarterly report, where the company beat EPS estimates, helping reinforce the view that results may be tracking better than expected. Article source
• Neutral Sentiment: There was also a GBS awareness-related press item over the weekend, but it did not include a clear business update or material financial catalyst for the shares. Article source

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.